Kymos is a CRO that provides development services for pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetics and nutraceuticals industries. The main areas of activity are the following ones: i) Immunogenicity studies and immunoassay of innovative biological drugs, biosimilars and vaccines. ii) Bioanalysis in preclinical and clinical studies, including full bioequivalence studies. iii) Quality control, stability studies and analytical development of drug substances and drug products (physico-chemical and microbiological testing) iv) Process analytical technology services, using NIR and RAMAN and QbD strategies. Kymos is certified in GLP's and GMP's compliance and it has been authorized as partial manufacturer in quality control.
| Website | https://www.kymos.com |
| Revenue | $29.6 million |
| Employees | 169 (169 on RocketReach) |
| Founded | 2001 |
| Phone | +34 935 48 18 48 |
| Industry | Pharmaceutical Manufacturing, Drug Stores & Pharmacies, Pharmaceutical, Retail, Health Care |
| Keywords | Contract Research Organization, Pharmaceutical Development, Biotechnology Development, Drug Development Services, Assay Development, Clinical Trial Services, Bioanalysis, Preclinical Studies, Analytical Testing, Biological Testing, Pharmaceutical Analysis, Veterinary Drug Development, Quality Control, Cosmetic Development, Nutraceutical Development, Regulatory Affairs, Scientific Research |
| Competitors | Covance, Syneos Health, ICON plc, Labcorp, Parexel, Charles River Laboratories, Eurofins, PPD, Medpace, WuXi AppTec +44 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Kymos employee's phone or email?
The Kymos annual revenue was $29.6 million in 2026.
Joan de Dou is the CEO of Kymos.
169 people are employed at Kymos.
The NAICS codes for Kymos are [3254, 325, 32, 32541].
The SIC codes for Kymos are [28, 283].